<span item_type="fundamental" item_id="a39f6dd3d0a9d21128b89c219ea6175f" counter_id="ST/US/CTKB" env="prod"></span><span item_type="announcement" item_id="645943592376145409" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 44.14 M, missing the estimate of USD 44.3 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.15.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -18.99 M.</p><p></p><h4>Segment Revenue</h4><ul><li>Product revenue for the first quarter of 2026 was $28,779 thousand, compared to $28,110 thousand in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Service revenue for the first quarter of 2026 was $15.4 million, a 15% increase compared to the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>. Service revenue was $15,356 thousand for Q1 2026, up from $13,347 thousand in Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Total recurring revenue, comprising service and reagent revenues, reached $18.4 million in the first quarter of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>On a trailing-12-month basis, recurring revenue accounted for 35% of total revenue, an increase from 31% as of the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>Gross Profit and Margin</h4><ul><li>GAAP gross profit was $21.3 million for the first quarter of 2026, a 5% increase compared to the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>. GAAP gross profit was $21,254 thousand for Q1 2026, compared to $20,157 thousand for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>GAAP gross profit margin was 48% in the first quarter of 2026, down from 49% in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Adjusted gross profit margin was 51% in the first quarter of 2026, compared to 52% in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>Operating Expenses</h4><ul><li>Total operating expenses were $39.7 million for the first quarter of 2026, a 13% increase compared to the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>. Total operating expenses were $39,717 thousand for Q1 2026, compared to $35,132 thousand for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Research and development expenses decreased by 1% to $9.6 million in the first quarter of 2026, from $9,725 thousand in Q1 2025 to $9,604 thousand in Q1 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Sales and marketing expenses decreased by 7% to $11.6 million in the first quarter of 2026, from $12,509 thousand in Q1 2025 to $11,646 thousand in Q1 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>General and administrative expenses increased by 43% to $18.5 million in the first quarter of 2026, from $12,898 thousand in Q1 2025 to $18,467 thousand in Q1 2026, primarily due to litigation-related expenses, outside consulting expenses, and bad debt reserves <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>Profitability</h4><ul><li>Loss from operations was - $18.5 million in the first quarter of 2026, compared to - $15.0 million in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Net loss in the first quarter of 2026 was - $18.9 million, compared to a net loss of - $11.4 million in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Adjusted EBITDA loss in the first quarter of 2026 was - $9.1 million, compared to an adjusted EBITDA loss of - $3.3 million in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>Cash and Marketable Securities</h4><ul><li>Cash and marketable securities totaled $262.2 million as of March 31, 2026, an increase of $0.7 million from $261.5 million as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Cash and cash equivalents were $65,665 thousand as of March 31, 2026, compared to $90,853 thousand as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li><li>Marketable securities were $196,560 thousand as of March 31, 2026, compared to $170,676 thousand as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>Operational Metrics (Installed Base)</h4><ul><li>Cytek Biosciences, Inc. expanded its total installed base to 3,789 instruments, adding 125 units in the first quarter of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul><h4>2026 Outlook</h4><ul><li>Cytek Biosciences, Inc. reaffirms its 2026 revenue guidance to be in the range of $205 million to $212 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>. This represents a projected growth of 2% to 5% over full year 2025, assuming no change from current currency exchange rates <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722dex991.htm"></span>.</li></ul>

Cytek Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 44.14 M